孕11–14周子宫下段瘢痕超声评估筛查剖宫产术后胎盘植入谱系疾病
前瞻性研究纳入535例有剖宫产史孕妇,在孕11+0至13+6周经阴道超声评估子宫下段瘢痕大小、位置及胎盘位置,将瘢痕位于宫颈峡部管上方且胎盘低置者定为高危。401例可显示瘢痕,其中23例高危,该方案筛查胎盘植入谱系疾病的敏感度100%、特异度95.31%、阳性预测值16.7%、阴性预测值100%。
要点
- 孕11–14周经阴道超声可显示约80%剖宫产史孕妇的子宫下段瘢痕。
- 瘢痕位于宫颈峡部管上方且胎盘低置覆盖暴露瘢痕提示胎盘植入谱系疾病高风险。
- 该筛查方案阴性预测值达100%,低风险者可基本排除后续胎盘植入谱系疾病。
关键影像表现/征象
- 子宫下段瘢痕按大小分为窄或裂开,按与宫颈峡部管关系分为位于其内或上方,共分四组。
- 胎盘位置分为高位或低置,瘢痕位于宫颈峡部管上方且胎盘低置时定为高危。
- 高危孕妇中2例于孕中期筛查发现胎盘植入谱系疾病,1例孕中期终止妊娠清宫时见胎盘粘连。
诊断标准与关键数值
- 瘢痕位于宫颈峡部管上方且胎盘低置覆盖暴露瘢痕为高危,瘢痕位于宫颈峡部管内和/或胎盘高位为低危。
- 该方案筛查胎盘植入谱系疾病敏感度100%(95%CI 29.24–100%)、特异度95.31%(95%CI 92.39–97.35%)。
- 阳性预测值16.7%(95%CI 5.8–39.2%)、阴性预测值100%(95%CI 98.4–100%)、阳性似然比21.33(95%CI 13.02–34.96)。
- 多因素回归显示仅母体BMI≥30 kg/m2与瘢痕位于宫颈峡部管上方显著相关(OR 2.42,95%CI 1.04–5.39;P=0.03)。
临床应用与阅片要点
- 孕11–14周经阴道超声应常规获取包含宫颈峡部管、子宫下段瘢痕及胎盘的正中矢状面。
- 重点观察瘢痕是否位于宫颈峡部管上方及胎盘是否低置覆盖瘢痕,两者并存提示高危。
- 筛查阴性者后续发生胎盘植入谱系疾病风险极低,可减少不必要随访。
局限性
- 单中心前瞻性研究,高危组仅23例,阳性预测值置信区间宽。
- 约20%孕妇未能显示子宫下段瘢痕,可能影响筛查适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To validate prospectively transvaginal ultrasound assessment of the lower uterine segment (LUS) scar at the time of first-trimester screening in women with previous Cesarean section (CS) and to determine its feasibility and accuracy in stratifying women according to the risk for placenta accreta spectrum (PAS) disorder.
METHODS: Women with a history of CS were recruited between 11 + 0 and 13 + 6 weeks' gestation and underwent LUS scar assessment using transvaginal ultrasound. A standardized midsagittal plane, which included the cervicoisthmic canal (CIC), the uterine scar and the placental site, was obtained. The scar was described in terms of its size (narrow or dehiscent) and its location in relation to the CIC (within or above), with each LUS scar classified into one of four groups based on these features. Placental location was assessed and classified as high- or low-lying. Women were stratified according to the risk of PAS, based on the relationship between the scar location and placental site. Women were considered high risk when the scar was above the CIC and the placenta was low-lying (i.e. when the placenta was overlying an exposed scar) and low risk when the scar was within the CIC and/or the placenta was high. High-risk patients were followed up at 20 weeks and 28-30 weeks for the development of PAS. Maternal demographics, detailed obstetric history and obstetric outcome were collected.
RESULTS: First-trimester transvaginal ultrasound was offered to 535 women with prior CS during the study period. A LUS scar was visualized in 79.9% (401/502) of those who agreed to undergo the examination. At this scan, the LUS scar was above the CIC in 9.0% (36/401) of women, but only 5.7% (23/401) additionally had a low-lying placenta overlying the scar. Of these 23 high-risk women, two were found to have PAS on the mid-trimester screening scan and one was noted to have placental adherence during evacuation following mid-trimester termination of pregnancy. On the first-trimester scan, 94.3% (378/401) of women were at low risk of PAS. This screening protocol yielded a positive likelihood ratio of 21.33 (95% CI, 13.02-34.96), sensitivity of 100% (95% CI, 29.24-100%), specificity of 95.31% (95% CI, 92.39-97.35%), positive predictive value of 16.7% (95% CI, 5.8-39.2%) and negative predictive value of 100% (95% CI, 98.4-100%). On multivariable regression analysis performed to identify confounding variables associated with a LUS scar above the CIC, only maternal body mass index ≥ 30 kg/m2 was significant (odds ratio (OR), 2.42 (95% CI, 1.04-5.39); P = 0.03). Although there was a trend towards an increased risk of a LUS scar above the CIC in women with prior elective prelabor CS (OR, 1.72 (95% CI, 0.80-3.68)), this association did not reach statistical significance.
CONCLUSIONS: Routine transvaginal ultrasound assessment of the location of the LUS scar and placenta at the time of first-trimester screening between 11 + 0 and 13 + 6 weeks' gestation in women with prior CS is a feasible and effective tool to identify those at risk of subsequent development of PAS disorder. A finding of placental implantation over an exposed LUS scar seems to be cardinal in predicting the risk of PAS disorder in women with prior CS, with an excellent negative predictive value. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bhatia A, Palacio M, Wright AM, et al. Lower uterine segment scar assessment at 11-14 weeks' gestation to screen for placenta accreta spectrum in women with prior Cesarean delivery. Ultrasound Obstet Gynecol. 2022. PMID: 34254386. doi:10.1002/uog.23734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。